Similar Items: Cancer risk associated with DPP4 inhibitors in type 2 diabetes: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS)
- Adverse events in different administration routes of Edaravone: A pharmacovigilance study based on the FDA adverse event reporting system
- Suicide adverse events associated with zopiclone and eszopiclone: A pharmacovigilance analysis based on FAERS, JADER and CVARD
- Disproportionality analysis of fondaparinux associated adverse events based on the FDA adverse event reporting system
- Exploring adverse events associated with vosoritide monotherapy: Insights from the FDA Adverse Event Reporting System
- Neuroprotective effects of DPP-4 inhibitors sitagliptin and vildagliptin in Parkinson’s disease via autophagy modulation
- Identifying High‐Risk Medications for Drug‐Induced Dystonia: A 20‐Year Retrospective Real‐World Pharmacovigilance Study Based on FAERS